(Q36924097)

English

Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells

scientific article published on April 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells (English)

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

6

object named as

David A Rizzieri

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

author name string

David J Adams

1

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Marit L Sandvold

2

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Finn Myhren

3

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Tove F Jacobsen

4

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Frank Giles

5

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

publication date

1 April 2008

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

49

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

4

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

786-797

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2562023

29 September 2017

Cellular resistance against troxacitabine in human cell lines and pediatric patient acute myeloid leukemia blast cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2562023

29 September 2017

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2562023

29 September 2017

Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2562023

29 September 2017

Sequential administration of irinotecan and cytarabine in the treatment of relapsed and refractory acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2562023

29 September 2017

Substrate cycles and drug resistance to 1-beta-D-arabinofuranosylcytosine (araC).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2562023

29 September 2017

Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinosylcytosine (ara-C) in leukemia and solid tumor cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2562023

29 September 2017

Modulation of cytarabine induced cytotoxicity using novel deoxynucleoside analogs in the HL60 cell line

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2562023

29 September 2017

Problems related to resistance to cytarabine in acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2562023

29 September 2017

Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2562023

29 September 2017

The role of purine analogue combinations in the management of acute leukemias

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2562023

29 September 2017

The interaction of gemcitabine and cytarabine on murine leukemias L1210 or P388 and on human normal and leukemic cell growth in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2562023

29 September 2017

Evaluation of synergism by a novel three-dimensional model for the combined action of cisplatin and etoposide on the growth of a human small-cell lung-cancer cell line, SBC-3.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2562023

29 September 2017

Biochemical modulation of arabinosylcytosine for therapy of leukemias

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2562023

29 September 2017

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2562023

29 September 2017

A three-dimensional model to analyze drug-drug interactions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2562023

29 September 2017

Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2562023

29 September 2017

Establishment and characterization of a human histiocytic lymphoma cell line (U-937)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2562023

29 September 2017

Ara-C: cellular and molecular pharmacology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2562023

27 June 2018

In vitro pharmacodynamic assay for cancer drug development: application to crisnatol, a new DNA intercalator.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2562023

27 June 2018

Potentiation of in vitro ara-C cytotoxicity by ribonucleotide reductase inhibitors, cyclin-dependent kinase modulators and the DNA repair inhibitor aphidicolin in paediatric acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1080%2F10428190801935752

21 January 2018

Psychological distress in men with breast cancer

1 reference

https://api.crossref.org/works/10.1080%2F10428190801935752

21 January 2018

Preclinical evaluation of gemcitabine combination regimens for application in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1080%2F10428190801935752

21 January 2018

A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1080%2F10428190801935752

21 January 2018

1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine (VNP40101M): I. Direct inhibition of O6-alkylguanine-DNA alkyltransferase (AGT) by electrophilic species generated by decomposition

1 reference

https://api.crossref.org/works/10.1080%2F10428190801935752

21 January 2018

Gemcitabine (2',2'-difluoro-2'-deoxycytidine), an antimetabolite that poisons topoisomerase I.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2562023

4 September 2018

Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/18398748

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antitumor activity of P-4055 (elaidic acid-cytarabine) compared to cytarabine in metastatic and s.c. human tumor xenograft models

1 reference

https://pubmed.ncbi.nlm.nih.gov/18398748

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1080/10428190801935752

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36924097&oldid=1663531287"